|
May 3
|
LivaNova First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 2
|
LivaNova PLC (NASDAQ:LIVN) Q1 2024 Earnings Call Transcript
|
|
May 1
|
LivaNova PLC (LIVN) Surpasses Analyst Revenue Forecasts in Q1 2024
|
|
May 1
|
LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates
|
|
May 1
|
LivaNova Reports First-Quarter 2024 Results
|
|
Apr 30
|
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
|
|
Apr 26
|
Livanova says patient data obtained in 2023 cyberattack
|
|
Apr 26
|
LivaNova gives notice of personal patient data compromised by hackers
|
|
Apr 25
|
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
|
|
Apr 25
|
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
|
|
Apr 24
|
LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?
|
|
Apr 15
|
Shareholders in LivaNova (NASDAQ:LIVN) have lost 34%, as stock drops 3.1% this past week
|
|
Mar 21
|
LivaNova to Announce First-Quarter 2024 Results
|
|
Mar 21
|
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
|
|
Mar 20
|
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
|
|
Mar 19
|
Returns On Capital Signal Difficult Times Ahead For LivaNova (NASDAQ:LIVN)
|
|
Mar 6
|
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
|
|
Mar 4
|
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
|
|
Mar 4
|
LivaNova to Present at the Barclays Global Healthcare Conference
|
|
Feb 5
|
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
|